{"brief_title": "A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs", "brief_summary": "The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94 in patients who previously have used anti-HIV drugs.", "detailed_description": "In this open-label study antiretroviral-experienced patients receive Combivir (3TC/AZT tablet) plus 1592U89 (abacavir) and 141W94 twice daily for 48 weeks.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Amprenavir", "criteria": "Inclusion Criteria Patients must have: - CD4 count greater than 50 cells/mm3. - HIV RNA less than 50,000 copies/ml. - No active AIDS (excluding CD4 count less than 200 cells/mm3). - Ability to comply with dosing schedule and protocol evaluations. Prior Medication: Allowed: AZT or non-nucleoside reverse transcriptase inhibitors (NNRTIs). Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms or conditions are excluded: - Active AIDS (not excluding CD4 count less than 200). - Malabsorption syndrome affecting drug absorption. - Serious medical condition that would compromise safety of the patient. Concurrent Medication: Excluded: - AZT or NNRTIs. - More than 1 week treatment with any protease inhibitor. - Enrollment in any other investigational drug protocol. Patients with the following prior conditions are excluded: History of clinically relevant pancreatitis or hepatitis within the past 6 months. Required: Antiretroviral therapy with either single or double reverse transcriptase inhibitors.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002217.xml"}